Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Fig. 3Fig. 3

PFS in patients with brain metastases (A; median follow-up was 54.7 months in patients with low NLR, and was not available for those with high NLR) and without brain metastases (B; median follow-up was 44.8 months in patients with low NLR, and was not available for those with high NLR); OS in patients with brain metastases (C; median follow-up was 54.7 months in patients with low NLR, and was not available for those with high NLR) and without brain metastases (D; median follow-up was 51.8 months in patients with low NLR, and 75.7 months in those with high NLR), according to high or low baseline NLR

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us